BioPharm International-06-15-2015

Quality-risk management tools can assist biopharma companies in mitigating risks when outsourcing crucial elements of the drug-development process.

Automation and disposables continue to reduce human error.

Contract service providers share insights on biopharma market developments and the implications of biosimilar drug approvals.

Important IP contractual provisions should be included when working with CMOs.

Whether outsourcing or developing cell therapies in-house, success demands a focus on quality, cost of goods, and sustainability from the start.